A Translational and Neurocomputational Evaluation of a Dopamine Receptor 1 Partial Agonist for Schizophrenia
Latest Information Update: 05 Sep 2024
At a glance
- Drugs PF 6412562 (Primary)
- Indications Schizophrenia and disorders with psychotic features
- Focus Therapeutic Use
- 01 Aug 2024 According to an AbbVie media release, AbbVie has acquired Cerevel Therapeutics.
- 01 Aug 2024 According to an AbbVie media release, AbbVie has acquired Cerevel Therapeutics.
- 07 May 2024 Status changed from recruiting to active, no longer recruiting.